Nanomedicine Strategies in Pancreatic Cancer Therapy

Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies, largely owing to its dense stromal barrier, hypovascular nature and profound immunosuppression. Nanomedicine seeks to overcome these obstacles by engineering carriers at the nanoscale to enhance delivery, specificity and therapeutic efficacy. Core approaches include liposomal and polymeric vesicles that exploit enhanced permeability and retention to accumulate in tumours, as well as stimuli-responsive systems that release payloads in response to pH, redox potential or enzymatic cues within the tumour microenvironment. DNA-based nanostructures, such as tetrahedral framework nucleic acids, have been adapted to ferry small activating RNAs or siRNA for gene modulation. Mesoporous silica and organosilica platforms enable co-delivery of chemotherapeutics and immunomodulatory agents, fostering immunogenic cell death and checkpoint blockade. Targeting of pancreatic stellate cells and remodelling of extracellular matrix rigidity have emerged as critical strategies to normalise stromal architecture and improve intratumoral penetration. Together, these innovations offer a multipronged arsenal against both the tumour parenchyma and its supporting niche, with the ultimate aim of translating into meaningful survival benefits.

Research from Nature Portfolio

Recent studies have harnessed co-delivery platforms to invoke robust antitumour immunity in pancreatic models. One approach conjugates an inhibitor of indoleamine 2,3‐dioxygenase to lipid prodrugs that self-assemble into nanovesicles or integrate within mesoporous silica nanoparticles; these constructs simultaneously deliver oxaliplatin to induce immunogenic cell death and relieve metabolic immunosuppression, resulting in potent cytotoxic T-lymphocyte recruitment and tumour eradication in orthotopic models. Another line of work targets the desmoplastic stroma by reprogramming activated pancreatic stellate cells: a tumour-responsive nanosystem co-encapsulates all-trans retinoic acid and siRNA against a collagen chaperone, reverting stellate cells to quiescence, reducing extracellular matrix deposition and thereby markedly improving chemotherapeutic uptake and efficacy.

Nanomedicine Strategies in Pancreatic Cancer Therapy publication trend

The graph below shows the total number of articles in nanomedicine strategies in pancreatic cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Stroma: The connective tissue and extracellular matrix surrounding tumour cells that can impede drug penetration.

Liposomal nanocarrier: A spherical vesicle composed of lipid bilayers used to encapsulate and deliver therapeutic agents.

Mesoporous silica nanoparticle (MSNP): A rigid, porous silica framework that enables high-capacity loading and co-delivery of multiple therapeutics.

Tetrahedral framework nucleic acid (tFNA): A self-assembled DNA nanostructure employed as a carrier for nucleic acid therapeutics such as siRNA or saRNA.

Immunogenic cell death (ICD): A form of cell death that releases danger signals and tumour antigens to stimulate adaptive immune responses.

IDO pathway: An immunosuppressive metabolic route involving indoleamine 2,3-dioxygenase that degrades tryptophan and dampens T cell activity.

Pancreatic stellate cell (PSC): A stromal cell type whose activation drives fibrotic desmoplasia in pancreatic cancer.

References

1. Rational design of a nonclassical liposomal nanoscale drug delivery system for innovative cancer therapy. BMEMat (2024).
2. Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid. Journal of Nanobiotechnology (2024).
3. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nature Communications (2017).
4. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nature Communications (2018).
5. Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1. Advanced Science (2021).